Veeva Link Now Available for 12 Therapeutic Areas Across More Than 50 Countries

Veeva Systems (NYSE: VEEV) today announced the availability of 11 new therapeutic areas in the Veeva Link customer intelligence platform. Initially started in oncology, Veeva Link delivers deep, curated expert profiles with real-time insights that help life sciences teams find and engage with global experts across twelve therapeutic areas.

“Veeva Link allows us to transform customer engagement by better connecting with key people, understanding the ecosystem around them, and making every interaction more relevant,” said Gandolf Finke, CEO at Fosanis. “Partnering with Veeva will help us bring our life-changing digital solutions to patients.”

Veeva Link delivers detailed information on key people — such as their expertise, collaborations, and scientific and digital activities. Dynamic profiles are sourced from thousands of publicly available data sources, including social media feeds, publications, clinical trials, events, and associations.

The expanded Veeva Link offering provides accurate and relevant data on influential stakeholders in bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology, in addition to its existing oncology solution.

“With our expansion to new therapeutic areas and the depth of our profiles, Veeva Link is setting the industry standard for real-time customer intelligence,” said Kilian Weiss, general manager for Veeva Link at Veeva Systems. “By tapping into a broad range of digital and scientific data sources and embedding these insights into Veeva’s Commercial Cloud, we are helping the healthcare community improve research and patient care.”

For more information on Veeva Link and the new therapeutic areas, watch the 2021 Veeva Commercial & Medical North America Summit Connect on-demand. The live online event featured sessions from top 20 pharmaceutical companies discussing how customer insights from Veeva Link are helping them drive more agile, personalized interactions and build stronger relationships, as well as from a rapidly growing biotech about using market-level insights to accelerate its first product launch.

Additional Information
For more on Veeva Link, visit:
Connect with Veeva on LinkedIn:
Follow @veevasystems on Twitter:

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit

Newmark Announces 8000 Sq. Ft of Office Leases in Philly

Over 8,000 Square Feet of Office Leases Signed in Philadelphia’s One South Broad Street

Building can accommodate life sciences conversion of remaining 108,000 square feet

Philadelphia, PA (June 8, 2021) — Newmark Real Estate (Newmark) announces 8,394 square feet of new office leases signed at One South Broad Street, centrally located adjacent to City Hall in Philadelphia, Pennsylvania. The leases were signed to law firms Williams Cedar (3,895 square feet) and Brown & Associates (2,475 square feet) and AWS, salesforce and data Integration consulting firm rockITdata (2,024 square feet). Newmark Managing Director Matt Guerrieri and Executive Managing Director Craig Scheuerle represented the landlord, AION Partners, in the leasing.

“As trial lawyers, we could not have found a better location in Philadelphia. Our new space is bright, efficient and convenient to our staff. It is just the kind of comfortable, collegiality-promoting workplace we were seeking,” said Gerald Williams, Founding Partner at Williams Cedar.

“We are thrilled to be in our new headquarters space at One South Broad Street,” said Marlie Andersch, CEO of rockITdata. “The workspace will provide our company the base for the exponential growth we expect over the next several years.”

One South Broad Street highlights the ability to convert nearly a quarter of the building (108,418 contiguous square feet), to life sciences space. The customizable space features lab-ready infrastructure; large, efficient and flexible floor plates; significant structural live load floor capability; 16’ to 20’ clear heights accommodating small and large molecule research; existing vertical shaft capacity to accommodate lab supply and exhaust needs and more.

“One South Broad Street is ready to accommodate the R&D laboratory market,” said Guerrieri. “The speed to market of this centrally located potential conversion makes it attractive to life sciences tenants who are seeking a space solution more readily available than new construction.”

About AION Partners

AION Partners is a vertically integrated owner and operator of multifamily and office real estate located throughout the Northeast. Founded in 2001, AION has acquired over 50 multifamily assets, comprised of nearly 19,000 units. AION’s primary focus is to deliver superior, risk-adjusted returns to its partners. We do so by surveying the macro-level real estate market, identifying undervalued and undercapitalized sectors with strong growth dynamics, and aggressively pursuing market-specific acquisitions. AION Partners along with their property management division, AION Management, creates value while maximizing yield and efficiently executing their business plans by utilizing active management techniques and favorable access to the capital markets. To learn more, visit

About Newmark

Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate services, with a comprehensive suite of investor/owner and occupier services and products. Our integrated platform seamlessly powers every phase of owning or occupying a property. Our services are tailored to every type of client, from owners to occupiers, investors to founders, growing startups to leading companies. Harnessing the power of data, technology, and industry expertise, we bring ingenuity to every exchange, and imagination to every space. Together with London-based partner Knight Frank and independently owned offices, our 18,800 professionals operate from approximately 500 offices around the world, delivering a global perspective and a nimble approach. In 2020, Newmark generated revenues in excess of $1.9 billion. To learn more, visit or follow @newmark.


Discussion of Forward-Looking Statements about Newmark

Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.


# # #




Science Center and Alira Health Establish Strategic Partnership to Accelerate MedTech Commercialization

PHILADELPHIA, PA – The University City Science Center, a Philadelphia-based nonprofit with over 60 years of experience advancing the commercialization of promising technologies, and Alira Health, a leading international healthcare and life sciences advisory firm, are joining forces to support Philadelphia-based life sciences and medical technology startups.

Through this partnership, Alira Health will leverage its expertise and deep connections within the healthcare and life sciences industry to support Science Center portfolio companies including members of the ic@3401 incubator and the Launch Lane cohort. Alira Health will offer a suite of advisory support, including expertise related to regulatory and clinical affairs, market access, reimbursement, in addition to health economics and outcomes research (HEOR).

“The Science Center’s partnership with Alira Health is a significant value-add for our portfolio companies, enabling them to more efficiently transition their technologies into the marketplace,” says Science Center President & CEO, Tiffany Wilson. “As we push further into the MedTech space, gaining access to Alira Health’s expertise is a win for Philadelphia’s life sciences ecosystem and positions our companies for the best chance of success.”

“Our partnership with the Science Center reinforces our commitment to fostering entrepreneurs in the development of innovative technologies in MedTech,” said David Uffer, Senior Partner and VP of MedTech, Alira Health. “The suite of programs they have developed to further their mission of supporting companies on their path to commercialization is exemplary in the Greater Philadelphia market. We are pleased to offer our practice leaders across our service offerings to advance this effort.”

In addition to individualized pro bono support of Science Center portfolio companies, David Uffer will hold office hours at the June 17th Venture Café Thursday Gathering focused on the MedTech sector. More info here.

The Science Center offers a suite of commercialization programs that are collectively designed to identify, support, and commercialize the most promising technologies. Supporting life sciences, MedTech, and tech-enabled startups, the Science Center helps put teams into place, identify early resources, and connect founders with its vast network of academic and research institutions and industry partners. Over the last ten years, the Science Center has supported over 600 startups and invested $13.4 million with over $1 billion raised in follow-on funds.

About the Science Center
Located in the heart of uCity Square, the Science Center is a mission-driven nonprofit that commercializes promising technology, cultivates talent and convenes people to inspire action. For over 50 years, the Science Center has supported startups, research, and economic development across the emerging technology sectors. As a result, Science Center-supported companies account for one out of every 100 jobs in the Greater Philadelphia region and drive $13 billion in economic activity in the region annually. By providing the right help at the right time, the Science Center is turning bright ideas into businesses and nurturing a workforce to support our 21st century economy. Visit to learn more.

About Alira Health
Alira Health is an international advisory firm on the frontlines of healthcare transformation. They provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.

Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Offices are located in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland.

Learn more at

Life Sciences Yields $24.6B for Greater Philadelphia

$6.3B in investments are woven into economic fabric of the region

January 4, 2016 (Philadelphia, PA) — The Greater Philadelphia Region (GPR) is positioned to lead the next stage of disruption within the spectrum of Life Sciences disciplines, thanks to its world-renowned research institutions, top biomedical programs, and a healthy ecosystem of small and large enterprises and investment activity, a new study shows. Greater Philadelphia Life Sciences Report, the joint study by Ben Franklin, BioAdvance, CEO Council for Growth, the Chamber of Commerce for Greater Philadelphia, EY, Life Sciences PA, the Greater Philadelphia Alliance for Capital and Technology (PACT), Philadelphia Works, Select Greater Philadelphia Council, and the University City Science Center, in collaboration with IHS Markit, explores Greater Philadelphia’s Life Sciences footprint and investment activity over the last five years and details the key findings that characterize the sector’s evolution in the region.

As previewed at PACT’s Impact 2016 event in November, the Greater Philadelphia Life Sciences Report details investments in Life Sciences companies from 2011 through the first half of 2016 and explores how the payoffs from those investments have been woven into the economic fabric of the region. It speaks to how the long-standing and continued importance of Life Sciences in the region is producing a broad range of sustainable employment opportunities and is increasing the importance of this sector to our export profile.

Click here to read the full press release.